Answers are grounded in this paper and cite their sources.
Background/Objectives: Excessive accumulation of visceral adipose tissue (VAT) is a significant contributor to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the diagnostic accuracy of the Metabolic Score for Visceral Fat (METS-VF) in identifying patients with MASLD compared with vibration-controlled transient elastography (FibroScan®) in the Slovak (Caucasian) population. Methods: A cross-sectional study of 156 obese/overweight patients, 61 males and 95 females, aged 33–78 years, treated for T2DM or prediabetes and MASLD, on oral antidiabetic medication, was conducted. We performed sex-stratified correlation analyses between METS-VF, the Controlled Attenuation Parameter (CAP) determined by FibroScan®, the Hepatic Steatosis Index (HSI), fat mass and lean mass parameters derived from dual-energy X-ray absorptiometry (DXA), and potential covariates. We fitted multiple linear regression models with CAP as the dependent variable and METS-VF as the independent variable, adjusted for age, sex, and the HOMA index. We then plotted ROC curves using HSI = 36 or a CAP value of 248 dB/m as a steatosis classifier. We then used logistic regression to evaluate the diagnostic value of METS-VF with a CAP of 248 dB/m. Results: We found a significant positive correlation between METS-VF and CAP (r = 0.26, p ≤ 0.001), HSI (r = 0.57, p ≤ 0.001), android fat% (r = 0.29, p ≤ 0.001), and total body fat% (r = 0.18, p ≤ 0.002). The AUC for the CAP in the model calculated from METS-VF and adjusted for the HOMA index, with HSI = 36 as a classifier, was 0.793 (95% CI 0.67–0.91). In the logistic regression analysis 1 SD increase in METS-VF was related to a 1.63-fold greater chance of MASLD in the whole group, (95% CI:1.08–2.46, p ≤ 0.02), AUC 0.661 (CI 0.52–0.79); and a 2.31-fold greater chance of MASLD in females (95% CI:1.20–4.44, p ≤ 0.01), AUC 0.795 (CI 0.66–0.93); in males the OR was statistically not significant (OR = 1.41, 95% CI: 0.76–2.62, p = 0.27), AUC 0.588 (CI 0.38–0.79). Conclusions: Our results demonstrated that METS-VF had a reasonable ability to correctly discriminate patients with MASLD, but with higher performance in the female group only.
No takes yet. Share an insight, caveat, or question.
Fraenkel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: